Yassine Labiad is a seasoned leader in in vitro diagnostics (IVD) and regulatory affairs, currently serving as a pivotal member of the Diagnostic Development team at Neuron23™ Inc. His expertise lies at the intersection of biotechnology, pharmaceuticals, and medical technology, where he has consistently driven...
Yassine Labiad is a seasoned leader in in vitro diagnostics (IVD) and regulatory affairs, currently serving as a pivotal member of the Diagnostic Development team at Neuron23™ Inc. His expertise lies at the intersection of biotechnology, pharmaceuticals, and medical technology, where he has consistently driven innovation in the development of diagnostic and therapeutic solutions. At Neuron23, a clinical-stage biotechnology company dedicated to precision medicine for genetically defined neurological and immunological diseases, Yassine plays a crucial role in advancing the company's mission through his extensive knowledge of regulatory frameworks, including CAP, CLIA, ISO standards, and the Medical Device Directive (MDD 93/42/EC).
In his current role, Yassine is involved in key projects that leverage cutting-edge technologies such as digital pathology, genomics, and machine learning to enhance diagnostic capabilities. His collaborative approach fosters strong partnerships across multidisciplinary teams, ensuring that new therapeutic products and medical devices—such as laboratory-developed tests (LDTs), companion diagnostics (CDx), and software as a medical device (SaMD)—are developed in compliance with Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) standards. Yassine's commitment to implementing effective Corrective and Preventive Action (CAPA) strategies further underscores his dedication to quality and safety in the development process. With a proven track record of bringing innovative solutions to market, Yassine Labiad continues to be a driving force in the evolution of precision diagnostics at Neuron23, shaping the future of healthcare for patients with complex genetic conditions.
